VR Logo

iTeos Therapeutics Inc. (ITOS) download report


Healthcare | Biotechnology & Pharma Research

iTeos Therapeutics Inc. (ITOS) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients.

IPO Date: 24-Jul-2020

Pres, CEO & Director: Dr. Michel Detheux Ph.D.

Chief Operating Officer: Mr. Matthew A. Call M.B.A.

Listing: NASDAQ: ITOS

Country: United States

Headquarters: Cambridge, MA

Website: https://www.iteostherapeutics.com

Key Facts

Market cap: $730.72 Mln

Revenue (TTM): $152.87 Mln

Earnings (TTM): $297.64 Mln

Cash: $823.98 Mln

Total Debt: $5.25 Mln

Insider's Holding: 0.27%

Liquidity: Low

52 Week range: $16.21 - 52.43

Shares outstanding: 35,540,700

Stock Performance

Time Period iTeos Therapeutics (ITOS) S&P BSE Sensex* S&P Small-Cap 600*
YTD-54.96-8.82-17.14
1 month24.52-3.22-4.85
3 months-37.01-7.40-12.74
1 Year-17.640.36-16.37
3 Years--10.307.97
5 Years--11.406.33
10 Years--12.0910.54
As on 27-Jun-2022 *As on 28-Jun-2022
Year iTeos Therapeutics (ITOS) S&P Small-Cap 600 S&P BSE Sensex
202137.6725.2721.99